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Abstract: The understanding of dry eye disease has advanced recently through increasing 
recognition that the etiology of the condition involves both tear evaporation and insufficient 
tear production, and that tear film instability and inflammation play roles in the various stages 
of the disease. Of significance, it has been recognized that lipid layer thickness correlates 
with tear film stability. The management of dry eye involves various strategies and therapeutic 
approaches that address one or more etiopathological components of the disease. The purpose of 
this review is to outline the characteristics and clinical utility of the Systane® ocular lubricants 
that contain hydroxypropyl-guar and one or both of the demulcents, ie, polyethylene glycol 400 
and propylene glycol. Clinically, these products are safe and are indicated for the temporary 
relief of burning and irritation due to dryness of the eye. In particular, this review describes the 
formulations, mechanisms of action, and clinical utility of the newest additions to this topical 
ocular lubricant family, Systane Ultra® and Systane Balance®. Both of these ocular products are 
formulated with an intelligent delivery system and both provide symptomatic relief to patients 
with dry eye. However, Systane Balance is a novel formulation that contains both polymer and 
lipid components designed to protect the ocular surface and replenish tear film lipids simul-
taneously, a factor that is of particular relevance to patients who have dry eye associated with 
meibomian gland dysfunction.
Keywords: Systane Ultra, Systane Balance, dry eye, hydroxypropyl-guar, meibomian gland 
dysfunction, dimyristoylphosphatidylglycerol
Introduction
Dry eye disease is a multifactorial ocular condition that results from an inadequate 
quantity of tear film and/or a disturbance of tear film stability. In 2007, the Interna-
tional Dry Eye Workshop subcommittee for definition and classification expanded 
the definition of dry eye disease, beyond tear deficiency and evaporation, to include 
tear film degradation and potential damage to the ocular surface.1 Additionally, this 
subcommittee recognized the contributions to the disease process of hyperosmolarity 
of the tear film and inflammation of the ocular surface.1
The moisture of the eye is maintained by the tear film, which consists of an aque-
ous layer (secreted by the lacrimal glands), a mucus layer (produced by conjunctival 
goblet cells and by corneal and conjunctival epithelial cells), and a lipid layer (secreted 
primarily by the meibomian glands).2–4 Any alterations in the volume, composition, 
distribution, and/or clearance of the tear film can lead to dry eye disease. Based on 
etiology, dry eye can be categorized as aqueous tear-deficient or evaporative.   Aqueous 
tear-deficient dry eye may be a result of Sjögren’s syndrome (primary disease or Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  secondary to other autoimmune diseases, such as rheumatoid 
arthritis or systemic lupus erythematosus) or non-Sjögren 
factors, including lacrimal gland insufficiency, lacrimal duct 
obstruction, or reflex hyposecretion. Evaporative dry eye may 
also be caused by several factors including, but not limited 
to, meibomian gland dysfunction, eyelid aperture disorders 
or lid/globe incongruity, blink disorders, and ocular surface 
disorders.2,5
The global prevalence of dry eye, estimated from large 
studies, ranges widely from approximately 5% to 35%.6 
Patients who suffer from dry eye have varying levels of 
symptoms, such as ocular dryness, burning, photophobia, 
foreign body sensation, grittiness, and redness, and may or 
may not have clinically meaningful signs, such as rapid tear 
film breakup time, increased osmolarity, and increased ocular 
surface staining.7,8 Individuals with dry eye also commonly 
experience disturbances in visual function, which have 
considerable negative impacts on their ability to carry out 
daily tasks (eg, driving and participating in sports and other 
leisure activities, such as reading and cooking).9 Since these 
limitations also have negative effects on overall quality of 
life, therapies that provide relief from the symptoms of dry 
eye are also likely to provide beneficial effects related to 
daily functioning and quality of life.10
The most common cause of evaporative dry eye disease 
is meibomian gland dysfunction, a condition associated 
with lipid insufficiency and/or poor lipid spreading, which 
results in a failure to form a continuous and homogeneous 
tear film. Ultimately, this failure leads to increased aque-
ous tear evaporation and decreased tear film stability.11,12 
Although the evaporation rate of the tear film is determined 
by multiple factors, including the protein constituents of the 
tear film, the mucin coating of the epithelial cells, and the 
aqueous component of lacrimal secretions, the status of 
the lipid layer is critical.11 In particular, the thickness of the 
lipid layer affects evaporation and a thicker tear film lipid 
layer is correlated with better tear film stability.13–15 Further, 
a recent study showed that the thickness of the lipid layer, as 
measured by interferometry, is well correlated with dry eye 
symptoms in routine clinical practice.16 Thus, an important 
feature of any dry eye therapy intended to provide relief to 
patients with meibomian gland dysfunction is the ability to 
mimic the lipid layer of the tears.
Management of dry eye disease
Over the past two decades, there has been substantial progress 
in the understanding of the etiological and pathophysiological 
aspects of dry eye disease. This has led to an evolution, not 
only in the way the disease is defined, but also in the way 
it is managed. Given the multifactorial nature of dry eye, 
management may involve various strategies and therapeutic 
approaches intended to minimize evaporative tear loss, sta-
bilize the tear film, protect the ocular surface, repair ocular 
surface damage, increase lubrication, enhance glandular 
secretion, and curb inflammation.17 In particular, the primary 
management goals are to restore the natural homeostasis of 
the ocular surface and tear film and to improve the patient’s 
ocular comfort and quality of life.9,18
Current approaches to the management of this condition 
include the use of topical lubricants (artificial tears or biologi-
cal tear substitutes), systemic antibiotics (eg, tetracycline, 
doxycycline, and minocycline), topical anti-inflammatory 
therapies (eg, corticosteroids or the immunomodulator, 
cyclosporin), nutritional therapies (eg, dietary intake of 
omega-3 fatty acids), and tear stimulants (eg, secretagogues, 
such as cholinergic agents). Additionally, the control of 
external factors associated with increased ocular dry-
ness (eg,   humidity) is a key component of managing the 
disease.3
Artificial tears
Dry eye results in disruption of the tear film and subsequent 
damage to epithelial cells on the ocular surface, which, in 
turn, may aggravate the observed signs and the symptoms of 
the disease experienced by the patient. While these damaged 
cells are being replaced, the ocular surface remains vulner-
able to further injury.19 According to the International Dry 
Eye Workshop report, early intervention could disrupt the 
core mechanism that drives dry eye1 and thus, by extension, 
an artificial tear with a demonstrated ability to restore ocular 
surface health may help to arrest progression of the disease. 
Regardless of the etiology and severity of dry eye, artificial 
tears are the mainstay of therapy.20 In addition to being safe 
and effective, the ideal topical ocular lubricant is character-
ized by its ability to spread efficiently, quickly, and evenly 
over the cornea, to minimize friction between the upper eyelid 
and the cornea, to cause minimal blur upon instillation, and 
to improve both the subjective symptoms and the objective 
signs of dry eye.20
Artificial tear formulations are typically buffered solu-
tions that contain electrolytes, surfactants, and one or more 
viscosity agents or lubricants, eg, guar-based and cellulose-
based derivatives, including hydroxypropyl-guar, as well 
as glycerin, dextran, polyvinyl alcohol, polyethylene glycol 
400, and propylene glycol, and may or may not also contain 
a preservative. Although most artificial tear products contain Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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similar ingredients, they differ in the types of lubricants used 
and in their mechanisms of action.4,21,22 Despite the avail-
ability of numerous marketed artificial tears, many of these 
products have been found to relieve the symptoms of dry eye 
only temporarily, rather than to heal the ocular surface or to 
treat the underlying cause of the disease.4 Given the draw-
backs of many currently available artificial tear formulations, 
and recognizing the advances in understanding of the global 
mechanisms underlying dry eye disease, the Systane® family 
of products (Alcon Laboratories Inc, Fort Worth, TX) was 
developed to address not only the tear film disorder, but also 
disruptions of the ocular surface itself.23
Systane family of lubricant eye  
drops
The Systane family of topical ocular products intended for use 
in patients with dry eye includes Systane lubricant eye drops, 
Systane preservative-free lubricant eye drops, Systane Ultra 
lubricant eye drops, Systane Ultra preservative-free lubricant 
eye drops, and, most recently, Systane Balance lubricant eye 
drops.24 These products, all of which include propylene gly-
col, hydroxypropyl-guar, and, with the exception of Systane 
Balance, polyethylene glycol 400, collectively represent a 
new generation of artificial tear preparations. They are theo-
rized to work through a unique biphasic mechanism of action 
in which the product first binds to damaged hydrophobic areas 
of epithelial cells to add volume to the tear film, and then 
restructures the tear film by forming a protective gel matrix 
that provides long-lasting protection.19 The high molecular 
weight (1000–5000 kDa) hydroxypropyl-guar molecules, 
along with the natural mucin layer, prolong retention of the 
demulcents on the ocular surface, which provides sustained 
lubrication to the eye and protects the ocular surface from 
further damage while the surface epithelial cells undergo 
repair and renewal.19,25
With the exception of the preservative-free formula-
tions, Systane lubricant eye drops are preserved with 
polyquaternium-1 (Polyquad®, Alcon Laboratories, Inc). 
  Polyquaternium-1 is a bactericidal quaternary ammonium 
compound that has been used as a preservative in contact 
lens storage solutions and lubricant eye drops. At the 
concentration used in Systane products (0.001%), this pre-
servative is safe and has been shown to have no effects on 
the cytokinetic movement, morphology, or mitotic activity 
of cultured human corneal epithelial cells after a 24-hour 
exposure period.26
In recent reviews and studies, evidence has been pro-
vided to show that in vitro, under conditions that mimic the 
ocular surface of a patient with dry eye, Systane exhibits 
a superior profile in the areas of tear film breakup time, 
extensional viscosity, coefficient of friction, and lubrication 
when compared with other marketed products, including 
saline solution, carboxymethylcellulose-containing formu-
lations like Refresh Tears® (Allergan Inc, Irvine, CA) and 
Optive™ lubricant eye drops (Allergan), and polyethylene 
glycol   400-containing Blink Tears® (Abbott Laboratories 
Inc, Abbott Park, IL), among others.20,21,27
In clinical studies, the daily use of Systane for 28 days 
or more in patients with dry eye has been consistently 
associated with significant decreases in conjunctival and/or 
corneal staining,7,19,23,28,29 increases in tear film breakup time 
(invasive or noninvasive),30–34 and improvements in patient-
assessed parameters (drop comfort, ocular comfort, and dry 
eye symptoms).7,19,28,29,33,34 Further, in several clinical studies 
comparing Systane with other marketed lubricant eye drops, 
Systane generally was superior to the active comparator or 
saline. Specifically, Systane was more effective in reduc-
ing ocular surface staining compared with Refresh Tears 
(0.5% carboxymethylcellulose),19 and was more effective in 
extending tear film breakup time compared with Sensitive 
Eyes® saline solution (Bausch and Lomb, Rochester, NY),35 
Lens Plus® saline solution (Advanced Medical Optics, Santa 
Ana, CA),32 Refresh Tears, and Refresh Endura® lubricant 
drops (carbomer 1342, castor oil, glycerin, mannitol, and 
polysorbate 80, Allergan).30 Additionally, in patients with 
dry eye, the administration of Systane was associated with 
a significantly greater (P , 0.05) ocular protection index 
relative to Refresh Tears and Refresh Endura at various time 
points after instillation;30 note that the ocular protection index, 
which is derived from the tear film breakup time and the blink 
interval, is often used as a surrogate measure of the level of 
ocular surface protection provided by the tear film.36 Finally, 
the combined use of Systane with cyclosporin 0.05% for 
6 months resulted in significantly greater (P , 0.05) reduc-
tions in corneal staining and the most common symptoms of 
dry eye (dryness, burning, grittiness, and foreign body sensa-
tion) when compared with the combined use of Refresh Tears 
and the same cyclosporin fomulation.37 Overall, a review of 
the clinical efficacy and safety of Systane reveals that this 
formulation yields long-lasting relief of dry eye symptoms, 
improves the signs associated with dry eye disease, provides 
an enhanced environment for ocular surface protection, and 
is well tolerated by patients with dry eye.21
While the Systane family of lubricant eye drops are indi-
cated for the temporary relief of burning and irritation due to 
dryness of the eye, Systane Ultra and Systane Balance deliver Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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extended ocular surface protection and symptom relief to 
patients with dry eye. Furthermore, Systane Balance was 
specifically designed for patients with dry eye associated 
with meibomian gland dysfunction. An overview of these 
recent additions to the Systane family follows.
Systane Ultra lubricant eye drops
Formulation and mechanism of action
Systane Ultra, like Systane, includes two demulcents (poly-
ethylene glycol 400 and propylene glycol) and a gelling 
agent (hydroxypropyl-guar); the product is also buffered 
with borate, which results in a partially crosslinked borate/ 
hydroxypropyl-guar gel.23,38 However, unlike Systane, 
  Systane Ultra includes sorbitol, which serves to optimize the 
viscosity of the drop through control of the aforementioned 
borate/hydroxypropyl-guar gel. In the bottle, the pH of Sys-
tane Ultra is 7.9 and the sorbitol/borate/hydroxypropyl-guar 
complexes are in a state of dynamic equilibrium. When a 
drop is instilled, the pressure exerted on the bottle to extract 
the drop reduces gel viscosity through shear thinning. Upon 
instillation, this physical process, along with ocular surface 
characteristics that dilute sorbitol and increase the density 
of the borate/hydroxypropyl-guar crosslinks, produces a gel 
of very low viscosity that is maintained between blinks.22 
The combined effect is intended to prevent blurring or haze 
upon instillation, reduce friction during blinking, and yield 
prolonged ocular comfort. Finally, the interaction of Systane 
Ultra with natural divalent ions in the tear film (eg, calcium, 
zinc, and magnesium) fortifies the borate/hydroxypropyl-
guar crosslinks and prolongs retention of the demulcents on 
the ocular surface.4,22,39
Clinical studies
The efficacy, tolerability, and/or safety of Systane Ultra 
have recently been evaluated in two clinical studies. The 
first of these was a prospective, double-masked, randomized, 
multicenter, parallel group study designed to evaluate the 
safety and efficacy of Systane Ultra relative to Optive, which 
contains 0.5% carboxymethylcellulose and 0.9% glycerin.40 
The second of these was a prospective, double-masked, 
randomized, single-center, parallel group study designed 
to evaluate the safety of Systane Ultra relative to Sensitive 
Eyes (isotonic saline solution).39
The safety and efficacy study included 113 patients, 
18 years of age and older, who had dry eye. After a 2-week 
run-in period during which patients administered aqueous 
saline eye drops four times daily in each eye, patients were 
randomized (1:1) to receive either Systane Ultra or Optive; 
the masked products were administered four times daily in 
each eye for 6 weeks. Efficacy was evaluated by comparing 
corneal and conjunctival staining scores, tear film breakup 
times, assessments of ocular symptoms (dryness, gritty/sandy 
sensation, burning, redness, crusting on eyelashes, and eyes 
sticking shut in the morning), Ocular Surface Disease Index 
scores, and responses to the Dry Eye Treatment Satisfaction 
and Visual Function-14 questionnaires; safety was assessed 
through a review of ocular examination findings and reported 
adverse events.
In the most critical sign-based indicators of long-term dry 
eye relief evaluated in this study (ie, reductions in corneal and 
conjunctival staining), Systane Ultra was found to be superior 
to Optive. Specifically, compared with patients in the Optive 
group, patients in the Systane Ultra group had significantly 
lower mean corneal staining scores at day 14 (P = 0.0009) 
and day 42 (P = 0.0106), and had significantly lower mean 
conjunctival staining scores at day 28 (P = 0.0475) and day 
42 (P = 0.0009). At the end of the study, patients in both study 
product groups reported high levels of satisfaction with their 
therapy and had significantly lower Ocular Surface Disease 
Index scores relative to baseline (P # 0.0013 for each pair-
wise comparison within each study product group). Further, 
patients in both study product groups reported significant 
decreases in the ocular symptoms (dryness, sandy/gritty 
feeling, and burning) associated with dry eye (P # 0.0021 
for all comparisons within study product groups between day 
42 and baseline). Finally, no patient experienced changes in 
slit lamp findings or visual acuity assessments, and, based 
on a review of reported adverse events, no safety signals 
were identified.40
The separately conducted safety study included 45 
patients who had dry eye and were successful contact lens 
wearers. In this study, patients were randomized (1:1) to 
receive either Systane Ultra or Sensitive Eyes. Regardless 
of study product assignment, patients instilled the masked 
lubricant into each eye 15 minutes prior to lens insertion 
(1–2 drops per eye), during the period of lens wear (at least 
one additional drop per eye), and immediately following lens 
removal (1–2 drops per eye). Safety was evaluated through a 
review of biomicroscopy results, visual acuity assessments, 
and corneal staining scores. In this study, no adverse events 
were reported and the use of Systane Ultra in successful 
contact lens wearers was not associated with any significant 
changes in corneal staining, biomicroscopy findings, or 
distance visual acuity.39 Overall, the results of these studies 
variously show that Systane Ultra is effective in reducing 
the signs and symptoms associated with dry eye, and is safe Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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when used by patients with dry eye. Of particular importance 
to safety, the lubricating eye drops are well tolerated among 
patients who wear contact lenses.
Systane Balance lubricant eye drops
Formulation and mechanism of action
While most artificial tears or topical ocular drops that replen-
ish the aqueous layer are designed to promote lubrication, 
they do not address the issue of lipid deficiency that is com-
monly associated with dry eye. Because this issue is critical 
for patients with evaporative dry eye in general, and patients 
with meibomian gland dysfunction in particular, Systane 
Balance, an hydroxypropyl-guar gellable lubricant eye drop 
containing micro-emulsions of oils (LipiTech™ system), was 
specifically formulated to minimize the evaporative loss of 
tears from the ocular surface.
Systane Balance contains propylene glycol,   hydroxypropyl- 
guar, borate, and sorbitol, and additionally includes both a 
polar phospholipid surfactant (dimyristoylphosphatidylglyc-
erol) and mineral oil.41 These latter two components were 
included to mimic the lipid layer of the tears. Specifically, 
polar lipids in the tear film are proposed to act as surfactants 
that help spread nonpolar lipids over the aqueous components 
of the tear film, thus providing a barrier between the two lay-
ers and a supportive structure for the nonpolar phase. It is the 
combination of this barrier and structure that creates a seal, 
which serves to decrease tear evaporation.17
A number of physicochemical studies were conducted 
with Systane Balance, including particle size measure-
ments from light scattering, droplet charge estimations from 
electrophoresis, viscosity and shear stress profiles from 
rheology, and coefficient of friction assessments from a 
specially designed tribometer. Additionally, interfacial and 
surface chemistry studies were performed using contact angle 
measurements to estimate surface tension and spreading 
pressure. Finally, light microscopy was used to document 
spreading and mixing properties of the emulsion, while 
electron micrographs were used to show the retention and 
release of oil droplets by hydroxypropyl-guar.   Collectively, 
data from these studies show that Systane Balance is a stable 
emulsion, with small droplet size, and low viscosity, which is 
adhesive on the ocular surface and can stabilize and structure 
interfaces.42
As a result of its low viscosity and neutral pH, Systane 
Balance is predicted to be comfortable when instilled, with 
minimal blurring. Prior to instillation (at pH 7), the drop 
has low viscosity, which allows for efficient mixing and 
spreading over the ocular surface. After instillation (at the 
higher pH of the ocular surface), the structured viscoelastic 
hydroxypropyl-guar polymer network forms, provides 
transient adherence to the ocular surface, and delivers the 
oil micelles over time. Specifically, blinking, dilution, and 
thermodynamic forces lead to the release of the oil from 
the polymer onto the ocular surface, forming part of the 
protective lipid layer of the tear film.46 Thus, in addition to 
its lubricant and surface-protective effects, Systane Balance 
can physically restore the tear film lipid layer.
Clinical studies
The efficacy and tolerability of Systane Balance was 
assessed variously in three clinical studies. The first was a 
randomized, double-masked, single-center, contralateral eye 
study designed to measure lipid layer thickness in dry eye 
patients who used Systane Balance compared with patients 
who used Soothe® XP eye drops (light mineral oil 1%, 
mineral oil 4.5%, octoxynol-40, and polysorbate-80, Bausch 
and Lomb).43 The second was a randomized, double-masked, 
single-center, two-period crossover study designed to evalu-
ate tear film breakup time, drop haze, ocular comfort, and 
drop acceptability in Systane Balance relative to Soothe 
XP. 43 Finally, the third was an open-label, single-center 
study designed to compare the efficacy of Systane Balance 
with that of habitual therapy in patients diagnosed with 
meibomian gland dysfunction.44
The first of the reported studies included 40 patients who 
had a baseline lipid layer thickness measuring less than 75 nm 
in both eyes, with less than 15 nm in variation over the course 
of a 10 minute observation period. In this contralateral eye 
study, one drop of Systane Balance was instilled in one eye 
of each patient and Soothe XP was instilled in the opposing 
eye; the eye that received each individual product was ran-
domized. The lipid layer thickness was measured at baseline 
and at minutes 1, 5, 15, 60, and 120 following instillation 
using a custom-designed lipid layer interferometer. While 
both of the products evaluated in this study contain lipid 
components, only Systane Balance contains an active demul-
cent, along with emulsifiers designed to form colloidally 
stable oil droplets.41 In this study, the instillation of Systane 
Balance resulted in a significantly greater thickening of the 
lipid layer relative to Soothe XP at all time points beginning 
at 5 minutes and continuing through 120 minutes postinstil-
lation (P # 0.0015 for each pairwise comparison at every 
time point).43 Thus, the study showed that, when compared 
with Soothe XP, instillation of Systane Balance produces a 
relatively rapid and substantially greater thickening of the 
tear film lipid layer.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The second of the reported studies included 38 patients 
with dry eye associated with meibomian gland dysfunction 
and a tear film breakup time of five seconds or less. In this 
study, all patients instilled a masked study product (Systane 
Balance or Soothe XP) into both eyes and were evaluated dur-
ing period 1; the patients subsequently instilled the alternate 
masked study product into both eyes and were reevaluated 
during period 2. The assignment of study product to each 
patient was randomized by period. Following study product 
instillation in each period, a haze/blur profile was created 
at 3 minutes, with determinations made at 30-second inter-
vals, tear film breakup time was evaluated at minutes 15, 
30, 60, and 120, and comfort and drop acceptability were 
assessed using a standard questionnaire. Overall, compared 
with Soothe XP, instillation of Systane Balance yielded 
significantly less haze up to 1 minute after instillation 
(P # 0.0044 for each time point comparison), resulted in 
significantly more favorable drop comfort scores after instil-
lation (P = 0.041), and produced significantly longer tear film 
breakup times at 120 minutes after instillation (P , 0.0001). 
While drop acceptability scores were better with Systane 
Balance than with Soothe XP, the differences did not reach 
statistical significance.43
The third of the reported studies included 49 patients 
who were previously diagnosed with meibomian gland 
dysfunction (defined by symptoms, as well as evidence of 
aberrant meibum and meibomian gland dropout). During 
the baseline visit, all patients reported detailed information 
regarding their habitual dry eye therapy uses. Following the 
baseline visit, and continuing for 28 days, all patients were 
instructed to use Systane Balance in place of their habitual 
therapies. The study endpoints included results from patient-
reported symptom relief questionnaires, tear film breakup 
times, corneal staining scores, assessments of quality for 
the expressed meibum, and reports of drop usage as tracked 
with an automated device (Medication Event Monitoring 
System). Each of the study endpoints was compared with 
the corresponding baseline measurement (ie, the assessments 
performed before instillation of Systane Balance that were 
the result of habitual therapy use).
The results from the patient questionnaires showed 
that 86% of the patients thought Systane Balance pro-
vided fast symptomatic relief, 79% were satisfied with the 
comfort of the Systane Balance drop, and 77% reported 
overall satisfaction with Systane Balance. After using the 
study product for 28 days, relative to habitual therapy, the 
patients had a mean improvement in tear film breakup time 
of 33% and a mean reduction in corneal staining of 26%; 
both results were significant (P = 0.032 and P , 0.001, 
respectively). Additionally, a mild improvement in meibo-
mian gland expression of 17% was observed and a moder-
ate decrease in drop usage of 24% was also reported; again, 
both results were significant (P = 0.005 and P , 0.001, 
respectively). Thus, Systane Balance was shown to be 
more effective in reducing the signs and symptoms of 
meibomian gland dysfunction than the patients’ habitual 
ocular therapies.44
Overall, these clinical studies demonstrate that topical 
ocular instillation of Systane Balance in patients with dry 
eye disease secondary to meibomian gland dysfunction 
is associated with substantial improvements in tear film 
lipid layer thickness and tear film stability up to 2 hours 
after instillation. Additionally, Systane Balance increases 
meibomian gland function and induces less haze (blur) 
upon instillation than a lipid-containing competitor prod-
uct; the blur profile for Systane Balance is similar to that 
of an aqueous-based competitor product. Finally, patients 
perceive Systane   Balance to be fast-acting, comfortable, 
and satisfactory; its use is associated with decreased drop 
dependency.
Conclusion
Current approaches to the management of dry eye disease 
reflect the multifactorial nature of this condition. Therapeutic 
strategies are designed to restore the natural tear film, protect 
the ocular surface, and improve the patient’s ocular comfort 
and quality of life. Artificial tears remain the mainstay of dry 
eye therapy. Although there are several marketed artificial tears 
available, many of these products have been found to relieve 
the symptoms of dry eye only temporarily, do not protect the 
ocular surface, and are not intended to address underlying 
causes of dry eye, particularly tear film lipid deficiencies. The 
Systane family of   hydroxypropyl-guar-containing gellable 
lubricant eye drops are formulated with an intelligent delivery 
system designed to provide symptomatic relief to patients with 
dry eye. The latest additions to the Systane family include 
Systane Ultra and Systane Balance. With the inclusion of 
sorbitol in its formulation, Systane Ultra causes minimal blur-
ring or haze upon instillation and provides prolonged ocular 
comfort and relief of dry eye symptoms. Systane Ultra has 
been formulated to provide optimal ocular surface protec-
tion and lubrication. Systane Balance contains a unique lipid 
emulsion, which simultaneously protects the ocular surface 
and replenishes tear film lipids, a factor that is of particular 
relevance to patients with dry eye associated with meibomian 
gland dysfunction.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Systane lubricant eye drops act in a complex manner to 
target multiple pathologies linked to dry eye disease. They 
offer extended relief of dry eye symptoms and provide an 
enhanced environment for ocular surface protection, with 
evident improvement of the signs associated with dry eye dis-
ease. Thus, to health care practitioners and patients, Systane 
Ultra and Systane Balance represent a good option for the 
management of dry eye, and in particular, Systane Balance 
provides the benefit of restoring the thickness of the tear film 
lipid layer in patients with dry eye secondary to meibomian 
gland dysfunction.
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